Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS6054136 A
Publication typeGrant
Application numberUS 08/838,893
Publication dateApr 25, 2000
Filing dateApr 11, 1997
Priority dateSep 30, 1993
Fee statusPaid
Publication number08838893, 838893, US 6054136 A, US 6054136A, US-A-6054136, US6054136 A, US6054136A
InventorsNabil Farah, Joel Denis
Original AssigneeGattefosse S.A.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Orally administrable composition capable of providing enhanced bioavailability when ingested
US 6054136 A
Abstract
Composition for pharmaceutical or cosmetic use, capable of forming a microemulsion, comprising at least:
an active principle,
a lipophilic phase consisting of a mixture of fatty acid esters and glycerides,
a surfactant (SA),
a cosurfactant (CoSA),
a hydrophilic phase,
characterized:
in that the lipophilic phase consists of a mixture of C8 to C18 polyglycolized glycerides having a hydrophilic-lipophilic balance (HLB) of less than 16, this lipophilic phase representing from 30 to 75% of the total weight of the composition;
in that the surfactant (SA) is chosen from the group comprising saturated C8 -C10 olyglycolized glycerides and oleic esters of polyglycerol, this surfactant having an HLB of less than 16;
in that the cosurfactant (CoSA) is chosen from the group comprising lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol;
in that the SA/CoSA ratio is between 0.5 and 6;
and in that the hydrophilic phase of the final microemulsion is supplied after ingestion by the physiological fluid of the digestive milieu.
Images(2)
Previous page
Next page
Claims(18)
We claim:
1. A pharmaceutical composition for oral administration, providing enhanced bioavailability when ingested and contacted with biological fluids of the body, comprising a lipophilic phase, a surfactant, a cosurfactant and a pharmaceutical active ingredient;
the lipophilic phase being present in an amount of from 1 to 75% by weight based on the total weight of the composition; the surfactant, cosurfactant and pharmaceutical active ingredient comprising the remainder and the ratio of surfactant to cosurfactant being between 0.5 and 6;
the lipophilic phase having a hydrophilic-lipophilic balance (HLB) of less than 16 and being obtained by an alcoholysis reaction of polyethylene glycol and a starting oil, the oil consisting of a mixture of mono, di and triglycerides of fatty acids selected from the group consisting of caprylic, capric, lauric, myristic, palmitic, stearic, oleic, linoleic and linolenic acids, at least 60% by weight in respect of total fatty acids containing 12 and more carbon atoms;
the surfactant is a product, having an HLB of less than 16, obtained by an alcoholysis reaction of polyethylene glycol and a fraction of oil consisting of a mixture of triglycerides of fatty acids selected from the group consisting of caprylic and capric acids; and
the cosurfactant consisting of a polyvalent alcohol ester selected from the group consisting of lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol,
and where each of said lipophilic phase, surfactant, cosurfactant and pharmaceutical active ingredient are miscible and substantially anhydrous; said composition providing enhanced bioavailability when ingested and contacted with the biological fluids of the body.
2. The composition of claim 1 wherein the reaction product of the lipophilic phase is saturated to provide a composition which is solid at room temperature.
3. The composition of claim 1 wherein the reaction product of the lipophilic phase is unsaturated to provide a composition which is liquid at room temperature.
4. The composition of claim 1 wherein the lipophilic phase has an HLB of about 14.
5. The composition of claim 3 wherein the lipophilic phase has an HLB equal to 6 and is liquid at room temperature.
6. The composition of claim 1 wherein the lipophilic phase is from 50 to 75% of the weight of the composition.
7. The composition of claim 1 wherein the surfactant consists of oleic esters of polyglycerol having an HLB equal to 10.
8. The composition of claim 1 wherein the ratio of surfactant to cosurfactant is between 1 and 2.
9. A method of increasing the bioavailability of a pharmaceutical active ingredient which is difficult to dissolve, said method comprising:
providing a pharmaceutical composition for oral administration, said composition comprising a lipophilic phase, a surfactant, a cosurfactant and a pharmaceutical active ingredient;
the lipophilic phase being present in an amount of from 1 to 75% by weight based on the total weight of the composition; the surfactant, cosurfactant and pharmaceutical active ingredient comprising the remainder and the ratio of surfactant to cosurfactant being between 0.5 and 6;
the lipophilic phase having a hydrophilic-lipophilic balance (HLB) of less than 16 and being obtained by an alcoholysis reaction of polyethylene glycol and a starting oil, the oil consisting of a mixture of mono, di and triglycerides of fatty acids selected from the group consisting of caprylic, capric, lauric, myristic, palmitic, stearic, oleic, linoleic and linolenic acids, at least 60% by weight in respect of total fatty acids containing 12 and more carbon atoms;
the surfactant is a product, having an HLB of less than 16, obtained by an alcoholysis reaction of polyethylene glycol and a fraction of oil consisting of a mixture of triglycerides of fatty acids selected from the group consisting of caprylic and capric acids; and
the cosurfactant consisting of a polyvalent alcohol ester selected from the group consisting of lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol,
and where each of said lipophilic phase, surfactant, cosurfactant and pharmaceutical active ingredient are miscible and substantially anhydrous; said composition providing enhanced bioavailability when ingested and contacted with the biological fluids of the body; and
ingesting said composition whereby said composition contacts the biological fluids of the body and increases the bioavailability of the pharmaceutical active ingredient.
10. The method of claim 9 wherein the reaction product of the lipophilic phase is saturated to provide a composition which is solid at room temperature.
11. The method of claim 9 wherein the reaction product of the lipophilic phase is unsaturated to provide a composition which is liquid at room temperature.
12. The method of claim 9 wherein the lipophilic phase is from 50 to 75% of the weight of the composition.
13. The method of claim 9 wherein the ratio of surfactant to cosurfactant is between 1 and 2.
14. A method of administering a pharmaceutical active ingredient to a host such that the bioavailability of the pharmaceutical active ingredient is increased, said method comprising the steps of:
providing a pharmaceutical composition for oral administration, said composition comprising a lipophilic phase, a surfactant, a cosurfactant and a pharmaceutical active ingredient;
the lipophilic phase being present in an amount of from 1 to 75% by weight based on the total weight of the composition; the surfactant, cosurfactant and pharmaceutical active ingredient comprising the remainder and the ratio of surfactant to cosurfactant being between 0.5 and 6;
the lipophilic phase having a hydrophilic-lipophilic balance (HLB) of less than 16 and being obtained by an alcoholysis reaction of polyethylene glycol and a starting oil, the oil consisting of a mixture of mono, di and triglycerides of fatty acids selected from the group consisting of caprylic, capric, lauric, myristic, palmitic, stearic, oleic, linoleic and linolenic acids, at least 60% by weight in respect of total fatty acids containing 12 and more carbon atoms;
the surfactant is a product, having an HLB of less than 16, obtained by an alcoholysis reaction of polyethylene glycol and a fraction of oil consisting of a mixture of triglycerides of fatty acids selected from the group consisting of caprylic and capric acids; and
the cosurfactant consisting of a polyvalent alcohol ester selected from the group consisting of lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol, and where each of said lipophilic phase, surfactant, cosurfactant and pharmaceutical active ingredient are miscible and substantially anhydrous; said composition providing enhanced bioavailability when ingested and contacted with the biological fluids of the body; and
administering said composition to said host for ingestion, whereby said composition contacts the biological fluids of the body and increases the bioavailability of the pharmaceutical active ingredient.
15. The method of claim 14 wherein the reaction product of the ipophilic phase is saturated to provide a composition which is solid at room temperature.
16. The method of claim 14 wherein the reaction product of the lipophilic phase is unsaturated to provide a composition which is liquid at room temperature.
17. The method of claim 14 wherein the lipophilic phase is from 50 to 75% of the weight of the composition.
18. The method of claim 14 wherein the ratio of surfactant to cosurfactant is between 1 and 2.
Description

This application is a continuation of application Ser. No. 08/433,489 filed May 12, 1995 which application is now abandoned.

TECHNICAL FIELD

The invention relates to a composition which can be administered, in particular, orally, for pharmaceutical or cosmetic use, capable of forming a microemulsion in situ with the biological fluid of the body; the invention relates more especially to a composition composed of a self-microemulsifying carrier system for active agents, designated in the art by the English term "SMEDDS" (self-microemulsifying drug delivery system); these systems have the property of emulsifying in water at the temperature of the human body.

This composition is intended, on the one hand to transport one or more soluble or sparingly soluble active agents, and on the other hand to form a microemulsion with the biological fluid of the human body, being understood that one or more active agentsor principles in solution in a microemulsion has better bioavailability.

PRIOR ART

As is known, a microemulsion is a fluid and stable homogeneous solution composed of four major constituents, respectively, a hydrophilic phase, a lipophilic phase, at least one surfactant (SA) and at least one cosurfactant (CoSA).

Microemulsions have been widely studied for oil recovery. There is hence no need to describe them here in detail.

A surfactant is a chemical compound possessing two groups, the first polar or ionic, which has a great affinity for water, the second which contains a longer or shorter aliphatic chain and is hydrophobic; these chemical compounds having marked hydrophilic character are intended to cause the formation of micelles in aqueous or oily solution.

A cosurfactant, also sometimes known as "co-surface-active agent", is also a chemical compound, but having hydrophobic character, intended to cause the mutual solubilization of the aqueous and oily phases in a microemulsion.

The invention is hence directed to increasing the bioavailability of active principles which are difficult to dissolve, by solubilizing them within a microemulsion.

In the document EP-A-0,334,777, the Applicant has shown the possibility of using microemulsions in the pharmaceutical industry. In the document WO 93/12766, the Applicant has described particular compositions for pharmaceutical use, in the form of microemulsions intended to be packaged in the form of suppositories, in which the hydrophilic phase is supplied by the rectal fluid. This production gives excellent results for suppositories, but cannot meet the needs for compositions intended to be ingested orally, since the amount of biological fluid in the stomach or intestine is much larger than in the rectum (several deciliters). Now, the conditions of existence of microemulsions such as those described in the document WO 93/12766 necessitate a very small percentage of water (few milliliters).

In the document EP-A-0,152,294, a system of the type in question has been described, consisting of a lipophilic phase composed of oleic alcohol and/or of polar esters of C2-C4 alcohols with C8-C12 fatty acids, and, as surfactant, ethoxylated glycerol, the mixture containing from 35 to 85% by weight of water. These formulations contain appreciable proportions of water, thereby ruling out the form of presentation in hard gelatin capsules. On the other hand, the compositions containing water form a macroemulsion in situ and not a microemulsion, thereby greatly decreasing the bioavailability.

In the document WO 93/23083, published after the priority date of the present application, a system is described in which the anhydrous hydrophilic phase consists of a polyglycolized glyceride containing C8-C10 short chains. This system does not significantly improve the diffusion of active principles through membranes. It does not enable hydrophilic active principles to be transported, and does not permit the formation of an emulsion, still less of a microemulsion in situ, thereby not facilitating bioavailability.

The pharmaceutical and cosmetic industries are expressing an ever increasing demand for compositions free from an aqueous phase, in order to facilitate their packaging in the form of hard gelatin capsules, tablets and plasters. The compositions known at the present time for the manufacture of hard gelatin capsules, in particular the ones described in the above documents, are unable to meet the need, since the presence of water contained in these mixtures is incompatible with the technique employing hard gelatin capsules.

The invention solves these problems. It relates to an orally administrable composition, in particular for pharmaceutical or cosmetic use, comprising a lipophilic phase, at least one surfactant and at least one cosurfactant which, mixed and in the presence of physiological fluid, form a microemulsion facilitating dissolution in situ and improving the bioavailability of the active principles.

DESCRIPTION OF THE INVENTION

This orally administrable composition capable of forming a microemulsion, comprising at least:

an active principle,

a lipophilic phase consisting of a mixture of fatty acid esters and glycerides,

a surfactant (SA),

a cosurfactant (CoSA),

a hydrophilic phase,

is characterized:

in that the lipophilic phase consists of a mixture of C8 to C18 polyglycolized glycerides having a hydrophilic-lipophilic balance (HLB) of less than 16, this lipophilic phase representing from 1 to 75% of the total weight of the composition;

in that the surfactant (SA) is chosen from the group comprising saturated C8 -C10 polyglycolized glycerides and oleic esters of polyglycerol, this surfactant also having an HLB of less than 16;

in that the cosurfactant (CoSA) is chosen from the group comprising lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol;

in that the SA/CoSA ratio is between 0.5 and 6;

and in that the hydrophilic phase of the final microemulsion is supplied after ingestion by the physiological fluid of the digestive milieu.

In other words, the invention consists in having selected a particular lipophilic phase which, combined with specific surfactants and cosurfactants, forms a microemulsion in the presence of the physiological fluid of the stomach and intestine of the human or animal body. In this way, it is not necessary to supply an external hydrophilic phase in order to produce this microemulsion. This composition improves the bioavailability of the active principles within the body. The composition according to the invention can thus be administered effectively via the oral route.

Surprisingly, the use of lipophilic phase having considerable chain length enables the diffusion through membranes and the passage of active principles or agents into the blood to be significantly improved.

In the description and in the claims:

"polyglycolized glycerides" denotes a mixture of mono-, di- and triglycerides and polyethylene glycol (PEG) mono- and diesters, preferably of molecular weight between 200 and 600, where appropriate of free glycerol and free PEG, whose HLB value is adjusted by the length of the PEG chain, and whose melting point is adjusted by the length of the chains of the fatty acids, of the PEG and by the degree of saturation of the fatty chains, and hence of the starting oil;

"C8 to C18 "-- also written C8 -C18 --"fatty acid" denotes mixtures in significant and variable proportions of caprylic (C8), capric (C10), lauric (C12), myristic (C14), palmitic (C16) and stearic (C18) adds when these acids are saturated, and of the corresponding C8 -C18 unsaturated acids. The proportions of these fatty acids can vary in accordance with the starting oils.

Advantageously, in practice:

the polyglycolized glycerides of the lipophilic phase are saturated, thereby enabling mixtures which are solid at room temperature and liquid at human body temperature to be produced; this mixture has an HLB of less than 16, preferably between 9 and 15 and advantageously in the neighbourhood of 14, of the type marketed by the Applicant under the registered trademark "GELUCIRE 44/14"; in effect, if the HLB value is greater than 16, the mixture becomes too hydrophilic, and this does not promote the microemulsion. It has been observed that best results are obtained when the HLB value is in the neighbourhood of 14, since microemulsions can be formed over a widest range.

in a variant, a mixture of unsaturated C8 -C18 polyglycolized glycerides, of HLB equal to 6 and which are liquid at room temperature, is used, such as the one marketed by the Applicant under the registered trademark "LABRAFIL WL 2609 BS";

the lipophilic phase represents from 1 to 75% of the weight of the composition, and preferably between 10 to 75% of the weight of the composition; it has been observed that, outside these limits, it is not possible to form a microemulsion which can be greatly diluted;

the surfactant (SA) is composed of C8 -C10 polyglycolized glycerides, of HLB less than 16 and preferably between 5 and 14, such as the ones marketed by the Applicant under the registered trademarks "LABRAFAC CM 10", "LABRAFAC HYDROPHILE" or "LABRASOL";

in a variant, the surfactant (SA) consists of oleic esters of polyglycerol, of HLB equal to 10, of the type marketed by the Applicant under the registered trademark "PLUROL OLEIQUE";

the cosurfactant (CoSA) is an ethyl diglycol, (also known as diethylene glycol monoethyl ether), such as the one marketed by the Applicant under the registered trademark "TRANSCUTOL";

in a variant, the cosurfactant (CoSA) consists of lauric esters of propylene glycol, of the type marketed by the Applicant under the registered trademark "LAUROGLYCOL";

in another variant, the cosurfactant (CoSA) consists of oleic esters of polyglycerol, of the type marketed by the Applicant under the registered trademark "PLUROL OLEIQUE";

the SA/CoSA ratio is between 0.5 and 6, and preferably between 1 and 2; above 6 and below 0.5, the composition does not give a microemulsion which can be greatly diluted.

One of the main values of the invention is that, irrespective of the amount of water supplied by the gastric or intestinal physiological fluid of the human or animal body (of the order of a few deciliters), the mixture composed of this amount of water and the composition will form a microemulsion, enhancing the solubility of the active principle or agent, which increases the bioavailability in spite of the appreciable proportion of this physiological fluid.

It was hence necessary to determine the ranges of existence of the microemulsions in question. To this end, pseudoternary diagrams were plotted, keeping to a surfactant SA/cosurfactant CoSA ratio of 1. Mixtures of lipophilic phase+SA+CoSA were made in different proportions. To each of these mixtures, the hydrophilic phase was then added dropwise until a clear solution was obtained. This amount added corresponds to the minimum percentage of the hydrophilic phase needed to enter the microemulsified range. This is the so-called entry percentage. Addition of the hydrophilic phase then continues until cloudiness appears. The amount added then corresponds to the so-called exit percentage.

This method of construction of pseudoternary diagrams is called the "titration method". The region of existence of the microemulsion, to wit a clear and transparent solution, lies between two regions of existence of an emulsion, a dispersion having a milky appearance.

While, most generally, the initial composition intended to be ingested does not contain water, it is nevertheless useful for some uses for this composition to contain water, with the proviso, however, that the latter does not initially participate in the formation of the final microemulsion.

In effect, when the composition takes liquid form, consequently hygroscopic in nature, and is intended to be packaged in the form of hard gelatin capsules, the presence of small proportions of water can be useful to balance the uptake of water contained in the encapsulation envelope. It will be readily understood that this water does not participate in the formation of the final microemulsion, but quite simply permits the stability of the capsule and prevents it becoming brittle.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a first pseudoternary diagram of a preferred composition of the invention.

FIG. 2 is a second pseudoternary diagram of a preferred composition of the invention.

FIGS. 1 and 2 show pseudoternary diagrams of two preferred compositions of the invention.

In both cases, the surfactant (SA)-cosurfactant (CoSA) mixture is the same. Only the lipophilic phase differs. In both diagrams, it is clearly apparent that the range of existence of the microemulsion is very wide and corresponds to a high percentage of hydrophilic phase (from 0 to 60% in FIG. 1, from 0 to 70% in FIG. 2).

Consequently, the microemulsion will be able to form even within the digestive system, where the amount of biological fluid is large (of the order of a few deciliters).

The examples which follow bring out preferred compositions of the invention. It is self-evident that the percentage of active principles is dependent on the dosage of the active principle administered.

In all the examples, the complement by weight to 100% of the composition is, in actual fact, represented by an anti-inflammatory active principle, namely indomethacin in Examples 1 to 8, 11 and 12, hydrocortisone in Example 9 and diclofenac sodium in Example 10.

EMBODIMENTS OF THE INVENTION EXAMPLE 1

As lipophilic phase, a mixture of saturated C8 -C18 polyglycolized glycerides having a melting point of 48∞C and an HLB of 9, marketed by the Applicant under the name "GELUCIRE 48/09", is used. This phase represents 73.7% of the total weight of the final composition.

The surfactant (SA)-cosurfactant (CoSA) mixture consists of a mixture of C8-C10 polyglycolized glycerides (SA), of HLB equal to 10, marketed by the Applicant under the name "LABRAFAC CM 10", and lauric esters of propylene glycol (CoSA) of the type marketed by the Applicant under the name "LAUROGLYCOL". This mixture represents 18.5% of the weight of the composition, and the SA/CoSA ratio is equal to 0.5.

The composition obtained is solid at room temperature and becomes liquid at 37∞C. It has many advantages compared to the traditional formulations used with the same active principle. An excellent power of solubilization of the active principle in the digestive milieu and an excellent bioavailability may be noted, despite the fact that this active principle is lipophilic.

Tests of in vitro dissolution in a gastric medium at pH 1.2 showed that, with this formulation, a percentage of 48% of the active principle dissolved at the end of one hour is achieved. By way of comparison, when the pure active principle (indomethacin) is tested, at best only 5% of this active principle is dissolved in one hour; and still by way of comparison, with hard gelatin capsules of this active principle which are currently on the market, only 4.7% of active principle dissolved is obtained at the end of one hour.

It could not be foreseen that the composition according to the invention would enable the dissolution of the active principles to be improved to this extent (nearly tenfold).

EXAMPLE 2

As lipophilic phase, a mixture of saturated C8 -C18 polyglycolized glycerides having a melting point of 44∞C. and an HLB of 14, marketed by the Applicant under the name "GELUCIRE 44/14", is used: this mixture represents 52.5% of the total weight of the final composition.

For the surfactant+cosurfactant mixture, the same components are used as in Example 1: this SA+CoSA mixture represents in this instance 35% of the weight of the composition, and the SA/CoSA ratio is equal to 0.5.

The same properties are observed as in Example 1.

EXAMPLE 3

The same lipophilic phase is used, and in the same proportion, as in Example 2.

The surfactant+cosurfactant mixture consists of the same surfactant as in Examples 1 and 2, combined with a cosurfactant consisting of ethyl diglycol, marketed by the Applicant under the name "TRANSCUTOL"; this SA+CoSA mixture represents 35% of the total weight of the final composition, and the SA/CoSA ratio is equal to 0.5.

EXAMPLE 4

The same lipophilic phase is used as in Example 2. This lipophilic phase represents 73.7% of the total weight of the final composition.

The same SA+CoSA mixture is used as in Example 2; this mixture represents 18.5% of the weight of the final composition, and the SA/CoSA ratio is equal to 0.5.

EXAMPLE 5

The same lipophilic phase is used, and in the same proportion, as in Example 2.

The surfactant+cosurfactant mixture consists of a mixture of oleic esters of polyglycerol, of HLB equal to 10, marketed by the Applicant under the name "PLUROL OLEIQUE" for the surfactant, the cosurfactant being the same as in Example 3, this mixture representing 35% of the weight of the composition, the SA/CoSa ratio being equal to 1.

This example is illustrated by the pseudoternary diagram of FIG. 1, in which the reference L denotes the lipophilic phase and the reference H the hydrophilic phase. The range of existence of the microemulsion is very wide, and corresponds to a high percentage of water (between 0 and 60%). In this way, the composition containing the active agents can be greatly diluted, thereby conferring on it a good solubilizing power in the digestive system and a good bioavailability of the active agents, something which could not be obtained hitherto.

EXAMPLE 6

As lipophilic phase, a mixture of saturated C8 -C1 polyglycolized glycerides having a melting point of 42∞C. and an HLB of 12, marketed by the Applicant under the name "GELUCIRE 42/12", is used.

The same surfactant+cosurfactant system is used as in Example 1, and the lipophilic phase is replaced by a mixture of saturated C8 -C18 polyglycolized glycerides having a melting point of 42∞C. and an HLB of 12.

This example is illustrated by the pseudoternary diagram of FIG. 2. The range of existence of the microemulsion is very wide, and corresponds to a high percentage of water (between 0 and 70%).

EXAMPLE 7

As lipophilic phase, a mixture of saturated C8-C18 polyglycolized glycerides having a melting point of 44∞C and an HLB of 14, marketed by the Applicant under the name "GELUCIRE 44/14", is used. This phase represents 45.2% of the total weight of the final composition.

As surfactant SA, the same mixture is used as in Example 1, in a proportion of 3.7% of the total weight of the composition.

As cosurfactant, the same compound is used as in Example 5, named "PLUROL OLEIQUE", in this instance acting as cosurfactant, in the proportion of 7.5%.

The SA/CoSA ratio is equal to 1 and the active principle (indomethacin) represents 43.5% of the total.

EXAMPLE 8

In vivo tests were conducted on rats with indomethacin as active principle.

The proportions by weight of the different constituents of this mixture are:

______________________________________Surfactant:  LABRASOL        44.90%Cosurfactant:        PLUROLOLEIQUE   15.00%Lipophilic phase:        LABRAFIL WL 2609 BS                        39.90%Active principle:        indomethacin    0.20%______________________________________

An oral administration of indomethacin is first carried out according to the above composition. The results show that, after one hour, the plasma concentrations lie between 5 and 7 micrograms per milliliter (g/ml), and after two hours between 7 and 13 g/ml.

A second series of tests consists in administering indormethacin orally in the form of powder made into a suspension immediately before use. It is found that, after one hour, the plasma concentrations lie between 1 and 5 g/ml, and after two hours between 1 and 4 g/ml. The kinetics obtained are irregular and vary from one animal to another.

The bioavailability is approximately twice as large in the case of the administration according to the invention.

EXAMPLE 9

In this example, the rates of dissolution of hydrocortisone in a gastric medium (at pH 1.2) are compared.

The same lipophilic phase and the same SA/CoSA mixture are used as in Example 8, but in the following proportions:

______________________________________Hydrocortisone  4.0%Lipophilic phase           19.2%Surfactant      57.6%Cosurfactant    19.2%______________________________________

In this way, it is possible to obtain a rate of dissolution in vitro ranging up to 50% in 45 minutes (min), whereas hydrocortisone in powder form displays a dissolution of 10% in 45 min.

EXAMPLE 10

In this example, the rates of dissolution in vitro in a gastric medium (at pH 1.2), in which diclofenac sodium in powder form is almost insoluble, are compared.

The proportions by weight of the different constituents of this

______________________________________Surfactant:  LABRASOL        38.40%Cosurfactant:        PLUROLOLEIQUE   38.40%Lipophillc phase:        LABRAFIL WL 2609 BS                        19.20%Active principle:        diclofenac sodium                        4.00%______________________________________

In this way, it is possible to obtain a rate of dissolution ranging up to 86% in 30 min, whereas diclofenac sodium in powder form has a rate of dissolution of 1% in the same time.

EXAMPLE 11

In this example, the rates of dissolution in vitro in a gastric medium (at pH=1.2), in which indomethacin alone has a rate of dissolution of less than 5% in the same medium, are compared.

The proportions by weight of the different constituents of this mixture are:

______________________________________Surfactant:  LABRASOL        57.60%Cosurfactant:        PLUROLOLEIQUE   19.20%Lipophilic phase:        LABRAFIL WL 2609 BS                        19.20%Active principle:        Indomethacin    4.00%______________________________________

A rate of dissolution of 57.1% in 30 min is obtained.

EXAMPLE 12

In this example, the same components are used as in the preceding example, with different proportions, namely:

______________________________________Surfactant:  LABRASOL        43.40%Cosurfactant:        PLUROLOLEIQUE   14.40%Lipophilic phase:        LABRAFIL WL 2609 BS                        38.40%Active principle:        Indomethacin    4.00%______________________________________

A rate of dissolution of 90% in 30 min is obtained. It is observed that an increase in the lipophilic phase improves the dissolution to a significant degree.

The compositions according to the invention have many advantages compared to the ones which are already known. The absence of an aqueous phase, which facilitates packaging of these pharmaceutical compositions, especially in the form of hard gelatin capsules, soft capsules, tablets or plasters, may be mentioned.

Thus, the invention may hence be administered orally.

It hence proves to be the case that the invention enables the choice both of the packaging and of the administration of compositions for pharmaceutical or cosmetic use to be broadened. Consequently, the industrial exploitation of the compositions according to the invention will be facilitated and may be contemplated successfully.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US5342625 *Dec 15, 1992Aug 30, 1994Sandoz Ltd.Hydrophilic phase of di-or partial ether and propylene glycol, lipophilic phase adn surfactant; immunmosuppressive, antiinflammatory, antiparasitic agent
EP0152945A2 *Feb 20, 1985Aug 28, 1985Müller, Bernd Willy Werner, Prof. Dr.Pharmaceutical multicomponent systems and process for their preparation
WO1993023083A1 *Apr 14, 1993Nov 25, 1993Agouron PharmaAnhydrous formulations for administering lipophilic agents
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6309665 *Feb 2, 2001Oct 30, 2001Gattefosse S.A.Composition with sustained release of active principle, capable of forming a microemulsion
US6652865 *Aug 22, 2001Nov 25, 2003Gattefosse HoldingFor decreasing the effect of intestinal metabolism on a drug
US6855733Feb 18, 2003Feb 15, 2005Soft Gel Technologies, Inc.Formulation and manufacturing process for coenzyme Q10 soft gel capsules
US6955820Aug 14, 2003Oct 18, 2005Soft Gel Technologies, Inc.Coenzyme Q10 formulation and process methodology for softgel capsules manufacturing
US7060263Aug 14, 2003Jun 13, 2006Udell Ronald GSuper absorption Coenzyme Q10
US7169385Mar 3, 2004Jan 30, 2007Ronald G. UdellSolubilized CoQ-10 and carnitine
US7220429Jul 27, 2005May 22, 2007Soft Gel Technologies, Inc.Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US7273606Aug 18, 2005Sep 25, 2007Soft Gel Technologies, Inc.Solubilized CoQ-10 and carnitine
US7273622Aug 8, 2005Sep 25, 2007Soft Gel Technologies, Inc.Soft gel capsule, beta-carotene; vitamin E; yellow beeswax;a mixture of mono-, di, tri-glycerides of 16 to 18 carbon chain length and polyglycerol oleate; rice bran oil
US7713523Sep 24, 2007May 11, 2010Soft Gel Technologies, Inc.Solubilized CoQ-10 and carnitine
US7736666Mar 6, 2001Jun 15, 2010Nicox S.A.Consists of naproxen, a butyl spacer and a nitrogen oxide (NO)-releasing nitrate group, linked together into a single molecule; useful as antiinflammatory agent and an analgesic
US7790905 *Dec 29, 2003Sep 7, 2010Mcneil-Ppc, Inc.sodium salt of celecoxib
US7815933Sep 5, 2002Oct 19, 2010Nicox S.A.Pre-concentrate emulsion of a nitrogen oxide-releasing NSAID, a surfactant, and an oil or fat, for oral administration; forming an oil-in-water emulsion with gastrointestinal fluids; side- effect reduction; bioavailability; treating pain and inflammation
US7842791Oct 17, 2003Nov 30, 2010Nancy Jean BrittenDispersible pharmaceutical compositions
US7887840Jun 20, 2002Feb 15, 2011Bend Research, Inc.Bioavailability of low- solubility drugs
US7927613Sep 11, 2003Apr 19, 2011University Of South FloridaPharmaceutical co-crystal compositions
US8105583Sep 29, 2004Jan 31, 2012Soft Gel Technologies, Inc.Solubilized CoQ-10
US8124072Sep 29, 2003Feb 28, 2012Soft Gel Technologies, Inc.sufficient quantity of limonene suitable to solubilize said coenzyme Q-10 and carnitine; and an acceptable carrier
US8147826Sep 9, 2005Apr 3, 2012Soft Gel Technologies, Inc.Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene
US8183290Jul 20, 2010May 22, 2012Mcneil-Ppc, Inc.Pharmaceutically acceptable propylene glycol solvate of naproxen
US8187615Dec 19, 2004May 29, 2012Doron FriedmanNon-aqueous compositions for oral delivery of insoluble bioactive agents
US8252326 *Jun 1, 2005Aug 28, 2012Catalent Australia Pty Ltd.Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10
US8343541Mar 14, 2008Jan 1, 2013Soft Gel Technologies, Inc.Ubiquinol and alpha lipoic acid compositions
US8362062Dec 24, 2003Jan 29, 2013Mcneil-Ppc, Inc.Pharmaceutical compositions with improved dissolution
US8492423Apr 3, 2012Jul 23, 2013Mcneil-Ppc, Inc.Pharmaceutical propylene glycol solvate compositions
US8506859Feb 28, 2012Aug 13, 2013Soft Gel Technologies, Inc.Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene
US8506995Jul 19, 2007Aug 13, 2013Soft Gel Technologies, Inc.Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US8536208Aug 20, 2008Sep 17, 2013Basilea Pharmaceutica AgAntifungal composition
US8617541Feb 2, 2012Dec 31, 2013Soft Gel Technologies, Inc.Solubilized CoQ-10
US8658161Jan 24, 2012Feb 25, 2014Soft Gel Technologies, Inc.Solubilized CoQ-10
US8802087Mar 22, 2005Aug 12, 2014Abbott Products GmbhPharmaceutical compositions of lipase-containing products, in particular of pancreation
US20090048322 *Jul 24, 2008Feb 19, 2009Diana Shu-Lian ChowParenteral and oral formulations of benzimidazoles
US20100273803 *Apr 27, 2010Oct 28, 2010Ceramoptec Industries Inc.Oral Formulations for Tetrapyrrole Derivatives
US20120301544 *Jan 18, 2011Nov 29, 2012Accucaps Industries LimitedPharmaceutical formulations of loratadine for encapsulation and combinations thereof
EP1728504A1 *Mar 23, 2005Dec 6, 2006Takeda Pharmaceutical Company LimitedEmulsion stabilizer
EP1728505A1 *Mar 23, 2005Dec 6, 2006Takeda Pharmaceutical Company LimitedPreparation with elevated content
EP2062571A1Nov 21, 2008May 27, 2009Innopharmax Inc.Self-emulsifying pharmaceutical composition with enhanced bioavailability
WO2003063868A1Jan 20, 2003Aug 7, 2003Leah Elizabeth AppelControlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
WO2005065652A1 *Dec 19, 2004Jul 21, 2005Doron FriedmanNon-aqueous composition for oral delivery of insoluble bioactive agents
WO2005089714A1 *Mar 23, 2005Sep 29, 2005Takeda PharmaceuticalEmulsion stabilizer
WO2008056822A1 *Nov 8, 2007May 15, 2008Takeda PharmaceuticalPharmaceutical composition comprising a dihydrobenzofuranyl isoindoline and a lipophilic component
WO2009024590A2Aug 20, 2008Feb 26, 2009Basilea Pharmaceutica AgAntifungal composition
WO2010039039A1 *Sep 23, 2009Apr 8, 2010Clavis Pharma AsaOral formulations of gemcitabine derivatives
WO2010147978A1Jun 15, 2010Dec 23, 2010Pfizer Inc.Dosage forms of apixaban
Classifications
U.S. Classification424/400, 424/439
International ClassificationA61K8/39, A61K9/107, A61K8/06, A61Q19/00
Cooperative ClassificationA61K8/375, A61Q19/00, A61K2800/92, A61K8/39, A61K8/068, A61K9/1075
European ClassificationA61K8/06M, A61K8/39, A61Q19/00, A61K9/107D, A61K8/37C
Legal Events
DateCodeEventDescription
Sep 17, 2011FPAYFee payment
Year of fee payment: 12
Sep 22, 2007FPAYFee payment
Year of fee payment: 8
Sep 29, 2003FPAYFee payment
Year of fee payment: 4
Mar 19, 2002ASAssignment
Owner name: GATTEFOSSE HOLDING, FRANCE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GATTEFOSSE, S.A.;REEL/FRAME:012745/0200
Effective date: 20011220
Owner name: GATTEFOSSE HOLDING 36 CHEMIN DE GENAS SAINT-PRIEST
Owner name: GATTEFOSSE HOLDING 36 CHEMIN DE GENASSAINT-PRIEST
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GATTEFOSSE, S.A. /AR;REEL/FRAME:012745/0200